Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459534 | 0.78 | PLG (0.39) | RIPK1KDRAURKAAURKBPLG | |
| SCHEMBL27737402 | 0.76 | CA12 (0.63) | TGFBR1AURKAAURKBNCF1MAP4K4 | |
| SCHEMBL5442223 | 0.76 | PIK3CD (0.52) | TGFBR1RIPK1KDRAURKBF12 | |
| SCHEMBL13459543 | 0.76 | DYRK1A (0.39) | RIPK1KDRPLGKITFLT3 | |
| SCHEMBL5444119 | 0.76 | TGFBR1 (0.52) | TGFBR1RIPK1AURKAAURKBF12 | |
| SCHEMBL5444085 | 0.75 | JAK2 (0.48) | TGFBR1RIPK1MKNK1MKNK2 | |
| SCHEMBL3974248 | 0.74 | NCF1 (0.55) | TGFBR1AURKAAURKBNCF1PRKCZ | |
| SCHEMBL29508482 | 0.74 | ALDH1A1 (0.59) | TGFBR1F12PLAUNCF1NOS3 | |
| SCHEMBL14931471 | 0.74 | ALDH1A1 (0.59) | TGFBR1F12PLAUNCF1NOS3 | |
| SCHEMBL5441099 | 0.73 | PI4K2A (0.49) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1689717-B1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LTD (GB) | 2007-12-26 | — | — | EP | disclosed |
| EP-1689717-B1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LTD (GB) | 2007-12-26 | — | — | EP | disclosed |
| EP-1689717-A1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049576-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | HRH4, NR1H2, NR1H3 | TGFBR1 1040/4885RIPK1 4712/4885KDR 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.